Allarity Therapeutics (ALLR)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	18.50 mm	18.50 mm	18.50 mm	18.50 mm	18.50 mm	18.50 mm
Cash burn (monthly)	244.33 k	(no burn)	4.10 mm	2.07 mm	1.81 mm	1.32 mm
Cash used (since last report)	1.32 mm	n/a	22.19 mm	11.18 mm	9.81 mm	7.13 mm
Cash remaining	17.18 mm	n/a	-3.69 mm	7.32 mm	8.69 mm	11.37 mm
Runway (months of cash)	70.3	n/a	-0.9	3.5	4.8	8.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

ALLR institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	5	13	-61.5%
Opened positions	1	9	-88.9%
Closed positions	9	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	1.92 mm	45.28 mm	-95.8%
Total shares	14.47 mm	5.98 mm	+142.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Streeterville Capital	9.00 mm	$1.49 mm	NEW
3i	2.99 mm	$0.00	0.0%
Forsakringsaktiebolaget Avanza Pension	1.37 mm	$259.00 k	0.0%
& Larsen ApS Sass	1.06 mm	$0.00	0.0%
Intracoastal Capital	45.21 k	$172.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Streeterville Capital	9.00 mm	+9.00 mm	NEW
Virtu Financial	0.00	-265.34 k	EXIT
Geode Capital Management	0.00	-102.33 k	EXIT
UBS UBS	0.00	-41.21 k	EXIT
Jump Financial	0.00	-38.80 k	EXIT
HRT Financial	0.00	-34.69 k	EXIT
Jane Street	0.00	-15.67 k	EXIT
Tower Research Capital	0.00	-12.16 k	EXIT
BAC Bank of America	0.00	-145.00	EXIT
Headlands Technologies	0.00	-20.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALLR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Jan 25	Laura Benjamin	Stock Options Common Stock	Grant	Acquire A	No	No	1.01	25,000	25.25 k	25,000
22 Jan 25	Vazzano Joseph Walter	Stock Options Common Stock	Grant	Acquire A	No	No	1.01	25,000	25.25 k	25,000
22 Jan 25	Thomas Jensen	Common Stock	Grant	Acquire A	No	No	0	396,734	0.00	396,734
22 Jan 25	Alexander Epshinsky	Common Stock	Grant	Acquire A	No	No	0	29,496	0.00	85,051
22 Jan 25	Jeremy R. Graff	Common Stock	Grant	Acquire A	No	No	0	144,441	0.00	262,924

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Allarity Therapeutics Announces That The Securities Class Action Lawsuit In The U.S. District Court For The Southern District Of New York Referenced In The Company's Form 10-Q Filing On November 11, 2024, Has Been Dismissed In Whole Against All Defendants

26 Feb 25

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a

Allarity Announces New Phase 2 Protocol For Stenoparib In Advanced Ovarian Cancer, To Focus On Dose Optimization And DRP Selection Criteria; Enrollment Targets Patients With Platinum-Resistant Disease; Study Aims To Enhance Understanding Of Wnt Pathway Impact

6 Feb 25

Allarity Therapeutics Announces Agreement In Principle With SEC To Resolve Investigation Related To 2022 Disclosures On FDA Meetings For NDA On Dovitinib; Settlement Approval Pending

30 Jan 25

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient